Search

Displaying results 3151 - 3160 of 10000 in total
  1. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    [A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion. … [L54903] Tradipitant has also been investigated in gastroparesis,COVID-19-induced pneumonia, and atopic dermatitis.[A275348, A275358, A275363]

  2. Drug

    Colfosceril palmitate

    go.drugbank.com/drugs/DB09114
    ApprovedWithdrawn

    Colfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome. … [T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.[L1109] Nowadays colfosceril palmitate is under the state of canceled post-marketing.

    Synonyms: Palmitate de colfosceril, Palmitato de colfoscerilo
  3. Drug

    Streptococcus pneumoniae type 17f capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10334
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: PNEUMOVAX 23 0,5 ML ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADET, PNEUMOVAX 23 Injektionslösung in einer Fertigspritze
  4. Drug

    Manganese citrate

    go.drugbank.com/drugs/DB14495
    Approved

    Mixtures: Collag-EN
  5. Drug

    Chromium picolinate

    go.drugbank.com/drugs/DB11255
    Approved

    Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss.

    Mixtures: GNC Lecithin 1200 Plus softgel CapsuleCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    ZD4407

    go.drugbank.com/drugs/DB06539
    Experimental

    It entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.

  7. Drug

    Gefapixant

    go.drugbank.com/drugs/DB15097
    Approved

    [L48596,L48591] It is the first therapy to be approved for the treatment of RCC or UCC in the EU.[L48601] … It received approval in both Japan and Switzerland in 2022 for the treatment of adult patients with RCC and UCC, and received subsequent approval in the EU in September 2023 for the same indications.

  8. Drug

    ME-344

    go.drugbank.com/drugs/DB13062
    Investigational

    ME-344 has been used in trials studying the treatment of Solid Tumors.

  9. Drug

    Endostatin

    go.drugbank.com/drugs/DB06423
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    TRK-250

    go.drugbank.com/drugs/DB18500
    Investigational

    TRK-250 is a small interfering RNA agent that targets human transforming growth factor-beta 1 (TGF-β1) messenger RNA.